BACKGROUND: Studies have shown that platelet-leukocyte aggregates (PLA) are sensitive to platelet activation which might exist before the onset of cerebral infarction. In this study, we investigated the formation of PLA in patients with cerebral infarction and the effects of antiplatelet agents on PLA. METHODS: The level of soluble P-selectin, C-reaction protein, platelet aggregation rate and leukocyte-platelet aggregations were measured in 40 patients with acute cerebral infarction and 20 normal controls. The 40 patients were randomly assigned to two treatment groups: aspirin group (n = 20) and clopidogrel group (n = 20). Both groups were monitored for Scandinavian stroke scale (SNSS), soluble P-selectin, serum C-reaction protein, platelet aggregation rate and PLA before and after the treatment. Flow cytometry was used to detect the levels of PLA in the blood. RESULTS: The percentage of platelet-monocyte aggregates (PMA) in patients with cerebral infarction was significantly increased compared with the controls (P < 0.001), which was positively correlated to soluble P-selectin, C-reaction protein and platelet aggregation rate (P < 0.05). After the treatment, the levels of PMA and platelet aggregation rate were decreased in both groups (P < 0.05). The level of PMA and platelet aggregation rate in the clopidogrel group was significantly lower than that in the aspirin group (P < 0.05). CONCLUSIONS:PMA are a sensitive biomarker to platelet activation in patients with cerebral infarction. In addition, although both aspirin and clopidogrel lowered the level of PMA, clopidogrel is a more effective treatment than aspirin in inhibiting platelet activation.
RCT Entities:
BACKGROUND: Studies have shown that platelet-leukocyte aggregates (PLA) are sensitive to platelet activation which might exist before the onset of cerebral infarction. In this study, we investigated the formation of PLA in patients with cerebral infarction and the effects of antiplatelet agents on PLA. METHODS: The level of soluble P-selectin, C-reaction protein, platelet aggregation rate and leukocyte-platelet aggregations were measured in 40 patients with acute cerebral infarction and 20 normal controls. The 40 patients were randomly assigned to two treatment groups: aspirin group (n = 20) and clopidogrel group (n = 20). Both groups were monitored for Scandinavian stroke scale (SNSS), soluble P-selectin, serum C-reaction protein, platelet aggregation rate and PLA before and after the treatment. Flow cytometry was used to detect the levels of PLA in the blood. RESULTS: The percentage of platelet-monocyte aggregates (PMA) in patients with cerebral infarction was significantly increased compared with the controls (P < 0.001), which was positively correlated to soluble P-selectin, C-reaction protein and platelet aggregation rate (P < 0.05). After the treatment, the levels of PMA and platelet aggregation rate were decreased in both groups (P < 0.05). The level of PMA and platelet aggregation rate in the clopidogrel group was significantly lower than that in the aspirin group (P < 0.05). CONCLUSIONS: PMA are a sensitive biomarker to platelet activation in patients with cerebral infarction. In addition, although both aspirin and clopidogrel lowered the level of PMA, clopidogrel is a more effective treatment than aspirin in inhibiting platelet activation.
Authors: Thomas Hilberg; Volker Schmidt; Doreen Gläser; Dominik Schammne; Wolfgang Lösche; Holger H W Gabriel Journal: Platelets Date: 2002 Aug-Sep Impact factor: 3.862
Authors: Yuqing Huo; Andreas Schober; S Bradley Forlow; David F Smith; Matthew Craig Hyman; Steffen Jung; Dan R Littman; Christian Weber; Klaus Ley Journal: Nat Med Date: 2002-12-16 Impact factor: 53.440
Authors: K Konstantopoulos; S Neelamegham; A R Burns; E Hentzen; G S Kansas; K R Snapp; E L Berg; J D Hellums; C W Smith; L V McIntire; S I Simon Journal: Circulation Date: 1998-09-01 Impact factor: 29.690
Authors: Jaydeep Sarma; Caterina A Laan; Shirjel Alam; Ashwani Jha; Keith A A Fox; Ian Dransfield Journal: Circulation Date: 2002-05-07 Impact factor: 29.690
Authors: Paul A Gurbel; Brian Galbut; Kevin P Bliden; Raymond D Bahr; Matthew T Roe; Victor L Serebruany; W Brian Gibler; Robert H Christenson; E Magnus Ohman Journal: J Thromb Thrombolysis Date: 2002-12 Impact factor: 2.300
Authors: Dominick J H McCabe; Paul Harrison; Ian J Mackie; Paul S Sidhu; Gordon Purdy; Andrew S Lawrie; Hilary Watt; Martin M Brown; Samuel J Machin Journal: Br J Haematol Date: 2004-06 Impact factor: 6.998